Skip to main content
CAMBIUM BIO LIMITED logo

CAMBIUM BIO LIMITED — Investor Relations & Filings

Ticker · CMB ISIN · AU0000327769 ASX Professional, scientific and technical activities
Open in API
Filings indexed 504 across all filing types
Latest filing 2021-11-17 AGM Information
Country AU Australia
Listing ASX CMB

About CAMBIUM BIO LIMITED

https://www.cambium.bio

Cambium Bio Limited is a clinical-stage regenerative medicine company focused on developing innovative cellular therapies to treat unmet medical needs in ophthalmology and inflammatory diseases. The company's primary focus is on its lead candidate, EluRegen, a first-in-class topical biologic designed for the treatment of corneal epithelial defects and dry eye disease. Utilizing its proprietary technology platforms, the company aims to harness the regenerative potential of biologics to provide effective treatments for chronic conditions. In addition to its ophthalmic pipeline, the company maintains assets in the field of mesenchymal stem cell therapies, including Progenza, which targets osteoarthritis and neuropathic pain. The company emphasizes a data-driven approach to clinical development, seeking to improve patient outcomes through advanced tissue engineering and cell-based solutions.

Recent filings

Filing Released Lang Actions
Chairman's Address to Shareholders 3 pages 172.4KB
AGM Information Classification · 95% confidence The document is titled 'AGM Chairman’s Address' and is an announcement dated 18 November 2021 related to Regeneus Ltd's 2021 Annual General Meeting. The content is a speech by the Chairman addressing shareholders at the AGM, discussing company progress, milestones, and future outlook. It explicitly states it is the Chairman's Address at the AGM, which is a presentation or material shared during the Annual General Meeting. The document length is 6781 characters, which is consistent with a detailed AGM address rather than a brief announcement or a full annual report. There are no detailed financial statements or comprehensive financial data that would classify it as an Annual Report (10-K) or Interim Report (IR). It is not a voting result, management change, or other categories. Therefore, the document fits the category of AGM Information (AGM-R).
2021-11-17 English
Results of Annual General Meeting 2 pages 174.7KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Results of Annual General Meeting held 18 November 2021' and provides detailed voting results for resolutions passed at the AGM. It references compliance with the Corporations Act 2001 and ASX Listing Rules, and includes proxy votes and poll results for each resolution. The content is focused on the official announcement of voting outcomes from the AGM, not the AGM materials or presentations themselves. The document length is 3302 characters, which is relatively short and consistent with a voting results announcement rather than a full AGM report or presentation. Therefore, this document fits the category of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2021-11-17 English
Supplementary Announcement - Appendix 4C 6 pages 342.5KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 17 November 2021, titled 'Quarterly Cashflow Report & Business Update' for the period ending 30 September 2021. It includes detailed quarterly cash flow statements, reconciliation of cash and cash equivalents, payments to related parties, financing facilities, and estimated cash available for future operating activities. The document references compliance with ASX Listing Rule 4.7B and includes the Appendix 4C form, which is a standard quarterly cash flow report required by the ASX for listed entities. The document contains substantive financial data and analysis for a quarter, not just an announcement or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is over 13,000 characters, indicating it is a full report rather than a brief announcement or certification. Q1 2022
2021-11-16 English
Amendment to Institutional Placement 1 page 138.5KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Regeneus Ltd regarding the extension of the second closing date for a share placement agreement with New Life Sciences Capital. It details the terms and timeline of the placement but does not contain financial statements or detailed financial analysis. The document length is short (2352 characters) and it is clearly an update on financing activity rather than a full financial report. Therefore, it fits the category of Capital/Financing Update (CAP).
2021-11-04 English
Investor Update Webcast - November 2021 1 page 118.
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 5 November 2021 regarding an investor update webcast held on 4 November. It provides a link to the webcast recording and a summary of the topics discussed, specifically company progress and strategy, but explicitly states that no financial updates were covered. The document is short (1495 characters) and serves as a notification about the webcast rather than containing detailed financial data or a transcript. It does not fit categories like Earnings Release, Interim Report, or Call Transcript because it lacks financial results or full call text. It is not a report publication announcement since it does not mention a report being published or attached. The best fit is Investor Presentation (IP) because it is an update aimed at investors focusing on company progress and strategy, typical of investor presentations or updates. Confidence is high given the clear description and content.
2021-11-04 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 336.6KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 29 October 2021, titled 'Quarterly Cashflow Report & Business Update – Period ending 30 September 2021'. It includes detailed financial data such as cash flow statements, operating cash outflows, investing and financing activities, and cash balances for the quarter ended 30 September 2021. The document also provides a business update on ongoing collaborations, research, and funding activities. The presence of the Appendix 4C quarterly cash flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly financial report. The document is comprehensive, contains substantive financial data and analysis for a period shorter than a full fiscal year, and is not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-10-28 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.